Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
A legfontosabb adatok
- Ki végzi
- Lingyi Biotech Co., Ltd.
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 1/2. fázis
- Résztvevők
- 18 fő, tervezett
- Kezdés
- 2026. jún. 15.
- Várható befejezés
- 2032. dec. 30.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoport
- A vizsgált kezelések
- LY-M003 Injection
- A regiszteradat frissítve
- 2026. július 2.
Ki vehet részt
The trial is looking for adults with Wilson's disease who are already on standard treatment. They get a single dose of the gene therapy LY-M003 Injection.
- Életkor
- 18 Years to 60 Years
- Nem
- All sexes
- A betegség stádiuma
- Confirmed Wilson's disease. People with decompensated cirrhosis or advanced liver disease, or a MELD score > 13, cannot join.
- Korábbi kezelés
- At least 6 months of standard therapy (for example D-penicillamine or zinc acetate) and at least 6 months of a low-copper diet before screening. No earlier gene therapy or cell therapy.
- Biomarker vagy leletérték
- Lab test showing a biallelic ATP7B gene mutation or deletion (both copies of the gene changed or missing). AAV8 neutralizing antibody titer must not be > 1:10.
- A részvétel fő kizáró okai
- Decompensated liver cirrhosis or advanced liver disease, or other liver diseases
- Positive test for hepatitis B, hepatitis C, HIV or syphilis
- Kidney disease on dialysis, or creatinine clearance < 60 mL/min
- Past or planned bone marrow, stem cell or organ transplant
- Pregnant or breastfeeding women, or women planning pregnancy
A regiszter összes feltétele (33)A regiszter feltételeinek elrejtése
Ki vehet részt
- The subject fully comprehends the purpose, design, methods and possible adverse events of the study, agrees to participate voluntarily and signs the informed consent form (ICF)
- Patients with confirmed diagnosis of Wilson's disease (WD)
- Subjects with Wilson's disease (WD) confirmed by laboratory testing to have biallelic ATP7B gene mutation or deletion
- The subjects are treated patients with Wilson's disease (WD) who have received standard therapy (e.g., D-penicillamine or zinc acetate) continuously for at least 6 months prior to screening
- Subjects have maintained a low-copper diet for at least 6 consecutive months prior to screening and will continue this dietary restriction throughout the study
- Subjects must agree to refrain from donating blood, organs, tissues or cells at any time after treatment
- Female subjects of childbearing potential (WOCBP) must have a negative pregnancy test
- Subjects and their partners must have no plans for pregnancy from screening through 6 months after study completion, and will voluntarily use effective contraception (e.g., abstinence, condoms). Subjects shall not plan to donate sperm or ova
Ki nem vehet részt
- AAV8 neutralizing antibody titer > 1:10
- Subjects with other concomitant liver diseases as judged by the investigator, including autoimmune hepatitis, alcoholic liver disease, primary biliary cholangitis, primary sclerosing cholangitis, and/or drug- or toxin-induced liver disease
- A history of non-compliance with copper chelators or zinc agents as assessed by the investigator within 6 months prior to screening
- Subjects who have received or plan to undergo bone marrow transplantation, hematopoietic stem cell transplantation and/or major organ transplantation, including but not limited to liver transplantation and renal transplantation
- Subjects with uncontrolled concomitant diseases or infectious diseases as assessed by the investigator
- Prior receipt of any type of gene therapy or cell therapy
- Use of systemic immunosuppressants or steroids within 3 months prior to administration (except for prophylactic immunosuppressive therapy specified in the protocol)
- Received live attenuated vaccines within 4 months prior to screening, or planned to receive such vaccines during the clinical trial
- Received treatment or intervention with other investigational drugs or study devices within 28 days or 5 half-lives (for drugs only) prior to screening, whichever is longer
- History of active gastrointestinal bleeding within the past 3 months
- Decompensated liver cirrhosis or advanced liver disease presenting with portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy, etc
- Model for End-Stage Liver Disease (MELD) score > 13
- Other disorders of copper metabolism, such as chronic cholestatic liver diseases, disorders of glycosylation, copper metabolism disorders, etc
- Subjects with positive hepatitis B surface antigen (HBsAg), positive hepatitis C virus (HCV) antibody, positive human immunodeficiency virus (HIV) antibody or positive treponema pallidum antibody
- Subjects with clinically diagnosed severe cardiovascular diseases or those deemed by the investigator to have such conditions (e.g., New York Heart Association [NYHA] heart failure classification ≥ Class 3)
- Subjects who are allergic to any ingredient of LY-M003 Injection
- History of cancer within 5 years prior to screening, excluding completely resected non-melanoma skin cancer, non-metastatic prostate cancer and fully cured ductal carcinoma in situ
- Other conditions that, in the investigator's opinion, render the subject ineligible for study participation
- Previously treated WD subjects with ALT and/or AST levels more than 5 times the upper limit of normal (ULN)
- Hemoglobin < 90g/L
- Subjects with end-stage renal disease on dialysis (Chronic Kidney Disease Stage 3 and above), or creatinine clearance < 60 mL/min
- Severe hyperlipidemia (triglycerides >1000 mg/dL)
- Subjects with severe hypersplenism complicated and requiring splenectomy as assessed by the investigator
- Subjects with severe neurological deficits or impairments that, in the investigator's judgment, compromise their safety and/or ability to participate in the study
- Pregnant women (or women planning pregnancy) or breastfeeding women
Alkalmassági kérdőív
Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.
- Életkor
- Wilson's disease
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a multicenter, open-label, single-arm, single-dose Phase I/II clinical study. It aims to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-M003 Injection in patients with Wilson's Disease (WD).
A vizsgálat 3 csoportja
- Phase 1: LY-M003 Dose group 1A vizsgált kezelés
Kezelés: LY-M003 Injection
- Phase 1: LY-M003 de-escalation doseA vizsgált kezelés
Kezelés: LY-M003 Injection
- Phase 2: LY-M003 Dose group 1A vizsgált kezelés
Kezelés: LY-M003 Injection
Következő lépések
Az orvosodnak
Kérdőlap az orvosnak
PDF az orvosodnak: mit vizsgál a vizsgálat, ki vehet részt, és 2 kérdés a részvételi feltételekről, hellyel a válaszoknak és a jegyzeteknek.
PDF, US Letter, 1–2 oldal. A4 méretben
A vizsgálati csapatnak
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multicenter, Open, Single-arm, Single-dose, Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Kérdések a feltételekről
- Forrás: NCT07641140: ki vehet részt
- A regiszteradat frissítve
- 2026. július 2.